Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
The Cardiovascular Diseases segment accounted for approximately 13.7% of market revenue in 2025 and is growing at a CAGR of 18.1% , driven by the expanding cardiovascular label and ongoing phase 3 programs evaluating semaglutide in heart failure with preserved ejection fraction (STEP-HFpEF), obese patients undergoing cardiac rehabilitation, and other cardiometabolic settings
Mounjaro (active ingredient: tirzepatide) subcutaneous injection Initial FDA Approval: 2022 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
They slow digestion, stabilize glucose levels, and reduce cravings
Open Field Activity System, Med Associates Inc., Georgia, VT, USA)
If serious gastrointestinal symptoms occur, the dose may be delayed or reverted to the previous dose until symptoms resolve
US$ 21.18
US$ 20.56
![Glutathione content [μg GSH · g-1 f.m.] in aboveground parts of spinach](https://www.researchgate.net/publication/288103263/figure/fig2/AS:597753772122113@1519527013152/Glutathione-content-mg-GSH-g-1-fm-in-aboveground-parts-of-spinach-in-individual.png)
US$ 21.14
US$ 21.38
US$ 20.07
